Latest / Breaking News To Trading Moves
The Novavax and Pfizer Adjuvant Platform Strategy
Pfizer licenses Novavax Matrix-M adjuvant for up to 2 vaccine programs
Novavax signed a non-exclusive licensing deal giving Pfizer access to Novavax’s Matrix-M adjuvant for use in vaccines targeting up to 2 infectious disease areas.
Novavax gets a $30M upfront payment in Q1 2026, is eligible for up to $500M in development and sales milestones, and tiered high mid-single-digit royalties on net sales of any Pfizer products that use Matrix-M. Pfizer controls development, manufacturing, and commercialisation, while Novavax supplies Matrix-M.
Why the market cares
1. This is a “platform…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.